Company Overview of Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc., a research-based pharmaceutical company, focuses on the discovery, development, and commercialization of molecules and therapies to help improve the lives of people who suffer from rare diseases. The company offers prescription pharmaceuticals for rare diseases that include tablets, oral solutions, sugar-free oral solutions, and injections; and capsules. It also offers nonprescription medicines and dietary supplements that help to support the normal functions of body. In addition, the company provides third party manufacturing services for customers in the United States, Canada, Mexico, Brazil, Europe, the Middle East, and Africa. Its products cover areas, su...
9841 Washingtonian Boulevard
Gaithersburg, MD 20878
Founded in 1980
Key Executives for Sigma-Tau Pharmaceuticals, Inc.
Senior Director of Finance
Chief Executive Officer of Sigma-Tau Group
Vice President of Medical Affairs
Vice President of Clinical Affairs
Compensation as of Fiscal Year 2014.
Sigma-Tau Pharmaceuticals, Inc. Key Developments
Sigma-Tau Pharmaceuticals, Inc. Announces Availability of CYSTARAN(TM) 0.44%
May 1 13
Sigma-Tau Pharmaceuticals, Inc. announced the availability of CYSTARAN(TM) (cysteamine ophthalmic solution) 0.44%, the first and only FDA-approved therapy for the treatment of corneal cystine crystal accumulation in patients with cystinosis. Sigma-Tau developed CYSTARAN in partnership with the National Institutes of Health (NIH) and in cooperation with the Cystinosis Foundation, the Cystinosis Research Foundation, and the Cystinosis Research Network. The U.S. Food and Drug Administration (FDA) approved CYSTARAN in October 2012, and the product has also been granted Orphan Drug status. CYSTARAN is available as a sterile ophthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride equivalent to 4.4 mg/mL of cysteamine (0.44%).
Sigma-Tau Pharmaceuticals, Inc. Promotes Dave Lemus to Chief Executive Officer
Apr 29 13
Sigma-Tau Pharmaceuticals, Inc. announced that Dave Lemus has been promoted to the newly created position of Chief Executive Officer, effective immediately. Mr. Lemus had served as Chief Operating Officer of the Company since March 2012, and joined the Company as Vice President of Finance in July 2011. Prior to joining Sigma-Tau Pharmaceuticals in 2011, Mr. Lemus was Executive Vice President and Chief Financial Officer of MorphoSys AG, where he launched Germany's first-ever biotechnology IPO in 1999. Mr. Lemus presently serves as Board Chairman of Proteros Gmbh in Munich, Germany, and as a Non-Executive Board Member of Toronto, Canada-based Axela Inc.
Sigma-Tau Pharmaceuticals, Inc. Announces U.S. Launch of VSL#3(R) JUNIOR
Oct 16 12
Sigma-Tau Pharmaceuticals, Inc. announced the U.S. launch of VSL#3(R) JUNIOR, a once-a-day, high-potency probiotic medical food for the dietary management of children who suffer from irritable bowel syndrome (IBS) and ulcerative colitis (UC). Unlike other marketed probiotics, VSL#3(R) JUNIOR is presently the only probiotic sold as a medical food for IBS and UC. Refrigerated VSL#3(R) JUNIOR contains 8 proprietary strains of 225 billion live bacteria, making it approximately 50 times more potent than the average probiotic. VSL#3(R) JUNIOR is natural and comes in a child-friendly watermelon flavor. It can be mixed into cold drinks, such as water and juice, or foods. Natural, VSL#3(R) JUNIOR is also gluten free, Kosher and Halal certified. Each box contains 30 of the watermelon flavored packets. VSL#3(R) JUNIOR is available nationwide, behind the counter, at participating pharmacies. As with all medical foods, the product must be used under medical supervision. In addition to VSL#3(R) JUNIOR, Sigma-Tau distributes three other formulations for adults: VSL#3(R) DS prescription-only medical food packets, containing 900 billion bacteria; VSL#3(R) packets, containing 450 billion bacteria, and; VSL#3(R) capsules, containing 112.5 billion bacteria.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|